BD (BDX)
Medical devices and connected systems spanning everyday care, drug delivery, monitoring, and intervention.
Something off on this page? Send us feedback.
Develops devices and consumables for medication delivery, specimen collection, patient monitoring, biopharma drug delivery, and surgical and vascular intervention. Revenue spans four segments and a global customer base, with recurring consumables alongside installed infusion, dispensing, and monitoring systems.
Develops and manufactures medical supplies and devices through Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The portfolio spans vascular-access and specimen-collection products; Alaris infusion and Pyxis medication-management systems; advanced patient monitoring; prefillable syringes and self-injection components; and urology, peripheral-vascular, oncology, and surgical tools.
Sells worldwide to hospitals and clinics, laboratories, pharmaceutical manufacturers, and other care providers, with the United States generating most revenue. Installed infusion, dispensing, and monitoring systems pair with recurring demand for disposable supplies and consumables.
Scale in high-volume essentials combines with integrated medication workflows, while acquired monitoring and interventional platforms broaden clinical coverage. Demand and market access depend on healthcare purchasing and reimbursement, regulatory authorizations and quality-system compliance, and access to raw materials, components, and sterilization capacity.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | RBC Capital | Reiterate | Rating: —Target: $180 | Target: $190 |
| Aug 7, 2026 | Stifel Nicolaus | Target | Target: $215 | Target: $195 |
| Aug 7, 2026 | RBC Capital | Reiterate | Rating: —Target: $175 | Target: $180 |
| Aug 6, 2026 | Jefferies | Reiterate | Rating: —Target: — | Target: $210 |
| Jul 28, 2026 | UBS | Initiate | Rating: —Target: — | Target: $190 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $709.0M · Total debt $16.81B · Total assets $50.73B · Shareholders' equity $24.42B
- Revenue
- $4.98B
- Operating income
- $663.0M
- Net income
- $377.0M
HistoryDividendAnnual yield
| Institutions | 97.23% | 267.90M shares | |
|---|---|---|---|
| 1,470 holders · as of Jun 30, 2026 | |||
| Insiders | 0.22% | 603.2K shares | |
| 31 holders · as of Sep 3, 2026 | |||
| Other | 2.55% | 7.04M shares | |
| remainder | |||
275.54M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
T. Rowe Price Associates, Inc.Institution | 9.24% | 25.46M | filed Feb 14, 2022 |
BlackRock, Inc.Institution | 8.93% | 24.59M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.53% | 17.99M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.44% | 15.00M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.43% | 14.97M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Michael Feld | officer: EVP, Chief Revenue Officer | −165 | $188.49 |
| Aug 13, 2026 | Thomas E. Jr Polen | director, officer: Chairman, CEO and President | −4,152 | $185.00 |
| Aug 11, 2026 | Roland Goette | officer: EVP and President, EMEA | −2,438 | $180.84 |
| Jul 27, 2026 | Michael Feld | officer: EVP, Chief Revenue Officer | −75 | $157.13 |
| Jun 26, 2026 | Michael Feld | officer: EVP, Chief Revenue Officer | −75 | $152.80 |
- Boston Scientific
Head-to-head in interventional vascular, urology, and oncology procedures.
- Baxter International
Direct infusion pump rival; Spectrum IQ contests Alaris for hospital contracts.
- Medtronic
Broadest medtech rival in vascular intervention, surgical, and GPO contracting.
- Johnson & Johnson
MedTech rival in surgical biosurgery, vascular, and hospital procedural markets.
- ICU Medical
Pure-play infusion rival; Plum pumps and LifeShield software contest Alaris.
- Teleflex
Vascular access rival; Arrow brand contests BD's PICC and central catheter lines.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BD | $183.12 | +0.07% | $50.42B | 55.1 | 13.8 | 2.4 | −9.6% |
| Boston Scientific | $44.75 | −0.39% | $66.77B | 18.3 | 13.6 | 3.2 | +7.5% |
| Baxter International | $23.73 | +0.21% | $12.24B | — | 11.3 | 1.1 | +5.3% |
| Medtronic | $90.08 | −0.76% | $116.19B | 22.4 | 15.0 | 3.1 | +13.7% |
| Johnson & Johnson | $268.52 | −0.25% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| ICU Medical | $164.03 | +1.89% | $4.02B | 136.4 | 18.5 | 1.9 | −0.2% |
| Teleflex | $123.74 | −0.93% | $5.53B | — | 13.4 | 2.1 | −27.0% |
| Median | 26.8 | 14.3 | 2.6 | +6.0% |